Key result
Preoperative GLP-1RA exposure is not linked to higher reoperation or revision risk after lumbar fusion.
Why the study?
Lumbar fusion-specific associations between preoperative GLP-1RA exposure and postoperative outcomes remain uncertain.
Does preoperative GLP-1RA exposure increase the risk of adverse surgical and postoperative outcomes in adults undergoing lumbar fusion?
Meta-Analysis (n=28,525)
Does preoperative GLP-1RA exposure increase the risk of adverse surgical and postoperative outcomes in adults undergoing lumbar fusion?
Odds Ratio: 0.74 (95% CI 0.44–1.24)
p-value: p=0.25
Preoperative GLP-1RA exposure does not appear to be an independent risk factor for adverse postoperative outcomes after lumbar fusion.
Preoperative GLP-1RA exposure shows no reoperation risk increase after lumbar fusion; supports safety signals but leaves open need for prospective confirmation.
Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used in patients with obesity and type 2 diabetes, but lumbar fusion-specific associations with postoperative outcomes remain uncertain. Objective To evaluate the association between preoperative GLP-1RA exposure and surgical and postoperative outcomes in adults undergoing lumbar fusion. Methods PubMed, Embase, and the Cochrane Library were searched from inception through 14 May 2026. Comparative studies of adults undergoing lumbar fusion with and without preoperative GLP-1RA exposure were included. Two reviewers independently screened studies, extracted data, and assessed risk of bias using the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I). Random-effects meta-analyses generated odds ratios with 95% confidence intervals. The protocol was prospectively registered in PROSPERO (CRD420261414637). Results Seven retrospective cohorts involving 28,525 patients were included; 6 used propensity score matching or another matching strategy. No statistically significant associations were observed between preoperative GLP-1RA exposure and reoperation or revision (OR: 0.74, 95% CI: 0.44–1.24; P = 0.25), postoperative infection (OR: 0.83, 95% CI: 0.68–1.00; P = 0.05), wound complications (OR: 0.86, 95% CI: 0.65–1.12; P = 0.26), or postoperative respiratory complications (OR: 1.08, 95% CI: 0.63–1.84; P = 0.69). Deep vein thrombosis, pulmonary embolism, and unplanned emergency department visits also did not differ significantly. All included studies were observational and predominantly used large administrative data sources. Conclusions Across the evaluated outcomes, the available observational evidence did not identify a signal of increased postoperative risk associated with preoperative GLP-1RA exposure after lumbar fusion. Prospective studies with standardized exposure definitions and perioperative management protocols are warranted to confirm these findings and better define their clinical implications. Clinical Relevance Current observational evidence does not establish preoperative GLP-1RA exposure alone as an independent risk factor for adverse outcomes after lumbar fusion. Level of Evidence 3.
No takes yet. Share an insight, caveat, or question.
Alves et al. (2026) conducted a meta-analysis in lumbar fusion (n=28,525). Preoperative GLP-1RA exposure vs. No preoperative GLP-1RA exposure was evaluated on reoperation or revision (OR 0.74, 95% CI 0.44-1.24, p=0.25). Preoperative GLP-1RA exposure was not significantly associated with increased risk of reoperation or revision (OR 0.74; 95% CI 0.44-1.24; P=0.25) after lumbar fusion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: